4.6 Article

Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes

Journal

PLOS ONE
Volume 12, Issue 2, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0172803

Keywords

-

Funding

  1. Fundacion CajaMurcia, Murcia, Spain [FFIS/CM10/011]
  2. Spanish Institute de Salud Carlos III [PI14/01637, CD13/00032]

Ask authors/readers for more resources

The primary cardiotoxic action of doxorubicin when used as antitumor drug is attributed to the generation of reactive oxygen species (ROS) therefore effective cardioprotection therapies are needed. In this sense, the antianginal drug nicorandil has been shown to be effective in cardioprotection from ischemic conditions but the underlying molecular mechanism to cope with doxorubicin-induced ROS is unclear. Our in vitro study using the HL-1 cardiomyocyte cell line derived from mouse atria reveals that the endogenous nitric oxide (NO) production was stimulated by nicorandil and arrested by NO synthase inhibition. Moreover, while the NO synthase activity was inhibited by doxorubicin-induced ROS, the NO synthase inhibition did not affect doxorubicin-induced ROS. The inhibition of NO synthase activity by doxorubicin was totally prevented by preincubation with nicorandil. Nicorandil also concentration-dependently (10 to 100 mu M) decreased doxorubicin-induced ROS and the effect was antagonized by 5-hydroxydecanoate. The inhibition profile of doxorubicin-induced ROS by nicorandil was unaltered when an L-arginine derivative or a protein kinase G inhibitor was present. Preincubation with pinacidil mimicked the effect of nicorandil and the protection was eliminated by glibenclamide. Quantitative colocalization of fluorescence indicated that the mitochondrion was the target organelle of nicorandil and the observed response was a decrease in the mitochondrial inner membrane potential. Interference with H+ movement across the mitochondrial inner membrane, leading to depolarization, also protected from doxorubicin-induced ROS. The data indicate that activation of the mitochondrial ATP-sensitive K+ channel by nicorandil causing mitochondrial depolarization, without participation of the NO donor activity, was responsible for inhibition of the mitochondrial NADPH oxidase that is the main contributor to ROS production in cardiomyocytes. Impairment of the cytosolic Ca2+ signal induced by caffeine and the increase in lipid peroxidation, both of which are indicators of doxorubicin-induced oxidative stress, were also prevented by nicorandil.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Surgery

Critical warm ischemia time point for cardiac donation after circulatory death

Silvia Sanchez-Camara, Mari C. Asensio-Lopez, Mario Royo-Villanova, Fernando Soler, Ruben Jara-Rubio, Jose Francisco Garrido-Penalver, Eduardo Pinar, Alvaro Hernandez-Vicente, Jose Antonio Hurtado, Antonio Lax, Domingo A. Pascual-Figal

Summary: This study aims to determine the critical warm ischemia time based on in vivo biochemical changes. The findings suggest that there is a significant compromise in cellular function and viability 10 minutes after circulatory arrest, which is important for incorporating DCD into heart transplant programs.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Article Medicine, General & Internal

Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics

Juan F. Delgado-Jimenez, Javier Segovia-Cubero, Luis Almenar-Bonet, Javier de Juan-Baguda, Antonio Lara-Padron, Jose Manuel Garcia-Pinilla, Juan Luis Bonilla-Palomas, Silvia Lopez-Fernandez, Sonia Mirabet-Perez, Ines Gomez-Otero, Antonio Castro-Fernandez, Beatriz Diaz-Molina, Josebe Goirigolzarri-Artaza, Luis Miguel Rincon-Diaz, Domingo Andres Pascual-Figal, Manuel Anguita-Sanchez, Javier Muniz, Maria G. Crespo-Leiro

Summary: The prevalence of hyperkalaemia in outpatients with heart failure and reduced ejection fraction (HFrEF) was estimated and its impact on achieving optimal medical treatment was evaluated in this study. The results showed that hyperkalaemia is a common problem in the management of heart failure patients and limits the optimization of medical treatment.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Geriatrics & Gerontology

Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome

Miriam Diez-Diez, Marta Amoros-Perez, Jorge de la Barrera, Enrique Vazquez, Ana Quintas, Domingo A. Pascual-Figal, Ana Dopazo, Fatima Sanchez-Cabo, Monica E. Kleinman, Leslie B. Gordon, Valentin Fuster, Vicente Andres, Jose J. Fuster

Summary: Clonal hematopoiesis of indeterminate potential (CHIP), the presence of somatic mutations in cancer-related genes in blood cells without hematological cancer, is an important risk factor for age-related conditions, especially cardiovascular disease. It is unknown whether CHIP plays a role in premature aging syndromes. Hutchinson-Gilford progeria syndrome (HGPS) is an ultra-rare genetic condition characterized by accelerated aging. This study investigated the prevalence of CHIP in HGPS patients and found that it is not frequent in HGPS, suggesting that it is unlikely to contribute to the pathophysiology of this accelerated aging syndrome.

GEROSCIENCE (2023)

Article Cardiac & Cardiovascular Systems

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure

Klaus K. Witte, Rolf Wachter, Michele Senni, Jan Belohlavek, Ewa Straburzynska-Migaj, Candida Fonseca, Eva Lonn, Adele Noe, Heike Schwende, Dmytro Butylin, YannTong Chiang, Domingo Pascual-Figal

Summary: The tolerability and dose up-titration patterns of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF) were comparable between patients with and without diabetes.

ESC HEART FAILURE (2023)

Article Cardiac & Cardiovascular Systems

Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

Phil McEwan, Cale Harrison, Rhona Binnie, Ruth D. Lewis, Alain Cohen-Solal, Lars H. Lund, Marcus Ohlsson, Stephan von Haehling, Josep Comin-Colet, Domingo A. Pascual-Figal, Sandra Wachter, Fabio Dorigotti, Antonio Ramirez de Arellano, Piotr Ponikowski, Ewa A. Jankowska

Summary: The study assessed the burden of disease and pharmacoeconomic implications of treating iron deficiency in patients with acute heart failure. The findings indicate that treatment with FCM can reduce hospitalizations and bed days, leading to savings in healthcare resources and improvement in quality of life for heart failure patients.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Editorial Material Cardiac & Cardiovascular Systems

Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring

Antoni Bayes-Genis, Domingo Pascual-Figal

EUROPEAN HEART JOURNAL (2023)

Article Cardiac & Cardiovascular Systems

Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the DAPA-MODA study

Domingo Pascual-Figal, J. Luis Zamorano, Mar Domingo, Herminio Morillas, Julio Nunez, Marta Cobo Marcos, Alejandro Riquelme-Perez, Albert Teis, Enrique Santas, Cesar Caro-Martinez, Jose Manuel Pinilla, Jose F. Rodriguez-Palomares, David Dobarro, M. Alejandra Restrepo-Cordoba, J. Ramon Gonzalez-Juanatey, Antoni Bayes Genis

Summary: The DAPA-MODA trial showed that dapagliflozin administration in stable chronic heart failure patients leads to global reverse remodelling of cardiac structure, including reductions in left atrial volume index, improvement in left ventricular geometry, and decreased concentrations of NT-proBNP.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Review Medicine, General & Internal

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

Jose Ramon Gonzalez-Juanatey, Josep Comin-Colet, Domingo Pascual Figal, Antoni Bayes-Genis, Jose Maria Cepeda, Jose M. Garcia-Pinilla, Antonio Garcia-Quintana, Luis Manzano, Jose Luis Zamorano

Summary: Heart failure requires a holistic approach that targets all neurohormonal systems, with vericiguat potentially playing a key role. The management of heart failure should be standardized at the local level, utilizing new technologies for remote monitoring and communication.

PATIENT PREFERENCE AND ADHERENCE (2023)

Article Medicine, Research & Experimental

Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55a/YY1/sST2 signaling axis

Antonio Lax, Fernando Soler, Maria Josefa Fernandez del Palacio, Silvia Pascual-Oliver, Miriam Ruiz Ballester, Jose Javier Fuster, Domingo Pascual-Figal, Maria del Carmen Asensio-Lopez

Summary: This study investigated the role of the YY1/HDAC4/sST2 axis in doxorubicin-induced cardiotoxicity and found that blocking miR-106b can prevent this toxicity.

MOLECULAR THERAPY-NUCLEIC ACIDS (2023)

Article Medicine, General & Internal

Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

Lourdes Vicent, Jesus Alvarez-Garcia, Rafael Vazquez-Garcia, Jose R. Gonzalez-Juanatey, Miguel Rivera, Javier Segovia, Domingo Pascual-Figal, Ramon Bover, Fernando Worner, Francisco Fernandez-Aviles, Albert Ariza-Sole, Manuel Martinez-Selles

Summary: The aim of this study was to determine the prognostic impact of coronary artery disease (CAD) on heart failure with reduced ejection fraction (HFrEF) mortality and readmissions. A total of 583 patients with left ventricular ejection fraction <40% were included in the study, among which 266 had CAD and 137 had idiopathic dilated cardiomyopathy (DCM). The study found that one-year mortality and readmissions were similar between patients with CAD and idiopathic DCM, but patients with idiopathic DCM were more likely to receive a heart transplant.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management

Manuel Barreiro-Perez, Pablo Pastor Pueyo, Sergio Raposeiras-Roubin, Dolores Montero Corominas, Aitor Uribarri, Rocio Eiros Bachiller, Jose Rozado Castano, Luisa Garcia-Cuenllas Alvarez, Luis Serratosa Fernandez, Fernando Dominguez, Domingo Pascual Figal

Summary: This document, drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology in collaboration with the Spanish Agency for Medicines and Health Products (AEMPS), aims to summarize the knowledge acquired since the start of the SARS-CoV-2 pandemic regarding the diagnosis and treatment of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.

REVISTA ESPANOLA DE CARDIOLOGIA (2023)

Article Cardiac & Cardiovascular Systems

Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients

Manuel Veas Porlan, Antonio Tello-Montoliu, Cecilia Lopez-Garcia, Pablo Gil-Perez, Miriam Quintana-Giner, Raquel Lopez-Galvez, Jose Miguel Rivera-Caravaca, Francisco Marin, Domingo Pascual Figal

Summary: This study aimed to investigate the impact of chronic renal failure on the pharmacokinetics and pharmacodynamics of ticagrelor. It was found that patients with renal impairment showed higher levels of ticagrelor after 4 and 6 hours of use, but there were no significant differences in platelet inhibition.

IJC HEART & VASCULATURE (2023)

Editorial Material Cardiac & Cardiovascular Systems

Personalizing anti-inflammatory therapy in heart failure: a new way

Domingo Pascual-Figal, Jose Javier Fuster, Antoni Bayes-Genis

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Review Medicine, General & Internal

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin

Carlos Escobar, Domingo Pascual-Figal, Luis Manzano, Julio Nunez, Miguel Camafort

Summary: Based on recent evidence, SGLT2 inhibitors, specifically dapagliflozin, are recommended as first-line therapy for managing heart failure patients, irrespective of ejection fraction, to reduce the burden of heart failure. Studies have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total heart failure hospitalizations, and MACE in the entire spectrum of heart failure, with sustained benefits over time. Full implementation of dapagliflozin in clinical practice leads to a substantial reduction in hospitalizations for heart failure and death in real-life populations.

JOURNAL OF CLINICAL MEDICINE (2023)

No Data Available